Compare KVHI & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVHI | ENLV |
|---|---|---|
| Founded | 1978 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.4M | 196.2M |
| IPO Year | 1996 | 2014 |
| Metric | KVHI | ENLV |
|---|---|---|
| Price | $11.55 | $0.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 146.1K | ★ 236.1K |
| Earning Date | 05-07-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $9,622,000.00 | N/A |
| Revenue This Year | $28.90 | N/A |
| Revenue Next Year | $31.85 | N/A |
| P/E Ratio | $358.00 | ★ N/A |
| Revenue Growth | ★ 3.82 | N/A |
| 52 Week Low | $5.09 | $0.66 |
| 52 Week High | $11.45 | $2.10 |
| Indicator | KVHI | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 66.97 | 35.04 |
| Support Level | $5.56 | $0.66 |
| Resistance Level | N/A | $1.25 |
| Average True Range (ATR) | 0.79 | 0.05 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 96.97 | 16.31 |
KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.